|
February 2002 (v02-n02) |
|
- Main Story - pgs. 1-22 AltaRex, Interneuron, Esperion Therapeutics
- Macro Market Commentary - pg. 23
- News Briefs - pgs. 24-25
- NIBM Model Portfolio & Updates - pgs. 26-28
|
 |
|
| This month's Main Story is actually three main
stories. We take a closer look at AltaRex (NASDAQ-OTC:ALTFF), Interneuron (IPIC), and
Esperion Therapeutics (ESPR). These three very different firms have their own charms to
potential investors. A "By Request" edition, this month's NIBM Newsletter
responds to our Subscriber's requests for a broader collection of companies in the NIBM
Model Portfolio. |
 |
|
| The following is an outline of this issue of
the NIBM Newsletter. |
Subscriber direct access |
|
| |
|
|
- Main Story
- Introduction
- AltaRex
- Summary
- Disclosure
- Introduction
- Table: Basic Facts
- Table: Selected monoclonal antibody vaccines
- Table: AltaRex product pipeline
- Table: Expression of target antigen on different cancers
- Technology
- OvaRex Trials
- The Berek/Ehlen study
- Table: OvaRex trials
- Table: New data on Berek/Ehlen study
- Important Items
- Coming Events
- Interneuron Pharmaceuticals
- Summary
- Table: Basic Facts
- Introduction
- Pagoclone
- Table: Pagoclone for treating anxiety disorders
- Table: Drug portfolio
- Table: Pagoclone agreements
- Table: Competitive profile
- Chart: Symptom improvement
- Table: Some potential competitors in clinical trials
- Table: Advanced clinical trials
- Tropsium for overactive bladder
- Table: Competitive profile
- Table: Competitive product comparisons
- Dersalazine for inflammatory bowel disease (IBD)
- Table: Basic facts about IBD
- Table: Dersalazine's basic components
- Table: Competitive products
- PRO-2000 for HIV and other sexually transmitted diseases
- Table: Coming events (2002)
- What can go wrong
- Esperion Therapeutics
- Summary
- Table: Basic Facts
- Introduction
- ETC-588 (LUV)
- Sidebar: Presentation Abstract
- ETC-216 (AIM)
- ETC-642 (RLT peptide)
- ESP-31015 (oral HDL)
- Competition
- Table: Selected Esperion competitors
- What can go wrong
- Macro Market Commentary
- News Briefs
- Biotech Monthly partner issues comprehensive restenosis report
- IDEC receives approval for first radiopharma product for NHL
- FDA proposes tighter disclosure rules for Advisory Comm.
members
- FDA gets temporary boss
- Erbitux might get 2003 approval after all
- NIBM Model Portfolio and Updates
- Three new members
- Dendreon
- Genta
- Titan Pharmaceuticals
|
|
|
| |
|
|
 |
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
